Premium
Bronchogenic carcinoma: Nitrogen mustard as a surgical adjuvant and factors influencing survival. University surgical adjuvant lung project
Author(s) -
Slack N. H.
Publication year - 1970
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197005)25:5<987::aid-cncr2820250502>3.0.co;2-g
Subject(s) - medicine , adjuvant , nitrogen mustard , pneumonectomy , adjuvant therapy , adenocarcinoma , surgery , lung cancer , oncology , basal cell , bronchogenic carcinoma , adjuvant chemotherapy , disease , cancer , chemotherapy , breast cancer , cyclophosphamide
Five‐year survival experience is reported for a series of 1,192 patients in the Collaborative Surgical Adjuvant Lung Study for the evaluation of nitrogen mustard (HN 2 ) as a surgical adjuvant. No beneficial effect from the use of HN 2 could be demonstrated. Postoperative complications were frequent in the control series (33%), but were significantly higher (45%) in the treatment series. Operative mortalities (within 30 days) occurred in 14% of the patients, being significantly higher after pneumonectomy (17%) than after lobectomy (9%). Five‐year survival was 44%, 23%, and 16% for therapeutic categories 1‐3, respectively. Five‐year survivors as a group were not completely distinguishable from short survivors, but more frequently had negative nodes and smaller tumors tending to be of the bronchiolar or squamous cell type, whereas short survivors more frequently had advanced disease and larger tumors tending to be of adenocarcinoma or anaplastic cell type. Factors with little influence on survival were age, race, sex, tumor location, and vascular invasion.